Pharmaceutical Executive February 14, 2025
The benefits for brand teams in bolstering their rapid-response capability.
In the post-COVID-19 healthcare landscape, pharmaceutical companies face novel challenges in engaging healthcare providers (HCPs). Access remains limited in many cases, demands on HCP attention are at an all-time high, and the proliferation of generics and biosimilars has intensified market competition. To succeed in this environment, brands must optimize their engagement across digital and field channels while ensuring their messages reach HCPs at precisely the right moment in the treatment decision journey.
The evolution of HCP targeting
Traditionally, HCP engagement has been largely retrospective, based on historical data that often arrives too late to influence critical treatment decisions. In today’s competitive environment, where commercial teams are asked to do more...
Today's Sponsors
Today's Sponsor